Durable versus biodegradable polymer drug-eluting stents in all-comers

Area of Science:

• Cardiovascular Medicine
• Biomaterials Science
• Interventional Cardiology

Background:

• Drug-eluting stents (DES) are standard for coronary angioplasty.
• Biodegradable polymer DES (BP-DES) were hypothesized to be superior to durable polymer DES (DP-DES) due to better biocompatibility.
• No prior studies confirmed the superiority of one polymer type over the other.

Purpose of the Study:

• To compare clinical outcomes between second-generation DP-DES and BP-DES in an all-comer population.
• To evaluate the safety and efficacy of different polymer types in DES.
• To assess the incidence of device-oriented composite endpoints and stent thrombosis.

Main Methods:

• Analysis of 2824 patients from the Cardio-FR database undergoing percutaneous coronary intervention (PCI).
• Inclusion of 2079 patients (1286 DP-DES, 793 BP-DES) with 2-year follow-up.
• Primary outcome: device-oriented composite endpoint (DOCE) including cardiac death, target vessel MI, and target lesion revascularization.

Main Results:

• Despite higher risk factors in the DP-DES group, acute stent thrombosis (ST) was significantly lower (HR 0.240, p=0.016).
• This ST difference remained significant after Cox regression and win ratio analysis.
• No significant difference in DOCE was observed between BP-DES and DP-DES at 2 years (12.1% vs 14.5%, p=0.158).

Conclusions:

• Clinical outcomes up to 2 years are similar for BP-DES and DP-DES.
• BP-DES are associated with a higher rate of acute stent thrombosis.
• Further research may be needed to understand the implications of polymer type on long-term cardiovascular outcomes.